A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution.
Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsidering the real risk of tardive dyskinesia associated with aripiprazole, particularly in the elderly.
North Alsace Mental Health Clinic (Etablissement Public de Santé Alsace Nord (EPSAN)), Brumath, France.
Edwige
E
Heitzmann
North Alsace Mental Health Clinic (Etablissement Public de Santé Alsace Nord (EPSAN)), Brumath, France.
Hervé
0000-0002-2682-7677
H
Javelot
Psychiatry Department, University Hospital of Strasbourg, Strasbourg, France.
Luisa
L
Weiner
OMEDIT Alsace, Faculté de Pharmacie-Laboratoire HuManiS (EA 7308), Service Pharmacie-CHRU de Strasbourg, Strasbourg, France.
Bruno
B
Michel